The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer.
Emmanouil S. Saloustros
No relevant relationships to disclose
Aristidis Polyzos
No relevant relationships to disclose
Charalampos Christophyllakis
No relevant relationships to disclose
Nikolaos K. Kentepozidis
No relevant relationships to disclose
Lampros Vamvakas
No relevant relationships to disclose
Kostas Kalbakis
No relevant relationships to disclose
Sofia Agelaki
No relevant relationships to disclose
Vassilis Georgoulias
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose